𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vaccination against feline leukaemia virus using a cell membrane antigen system

✍ Scribed by William Jarrett; Oswald Jarrett; Lindsay MacKey; Helen Laird; Christine Hood; David Hay

Book ID
102868518
Publisher
John Wiley and Sons
Year
1975
Tongue
French
Weight
526 KB
Volume
16
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Cats inoculated with live feline lymphoblastoid cells of the FL74 line developed high titres of antibody to feline oncornavirus‐associated cell membrane antigen (FOCMA). Eight cats were subsequently challenged with a large dose of feline leukaemia virus (FeLV) of a highly pathogenic strain. All resisted infection while 10 cats given the challenge virus alone became infected. The FeLV produced by FL74 cells was shown to be of extremely low infectivity in cats and in cultured feline cells. Cats inoculated with either FL74 cells or virus purified from them did not become infected. The purified virus did not induce FOCMA antibody in cats not previously exposed to FeLV. The fact that FL74 cells are highly immunogenic, but produce virus of low infectivity, is of value in devising vaccines against FeLV. Cats were also inoculated with FL74 cells which had been inactivated with paraformaldehyde. They developed FOCMA antibody, reaching a peak titre of 256, and no virus could be cultured either from the vaccine preparations or from the tissues of the cats.

📜 SIMILAR VOLUMES

Antibody-dependent cell-mediated cytotox
Antibody-dependent cell-mediated cytotoxicity against epstein-barr virus membrane antigen in african Burkitt's lymphoma
✍ David J. Granlund; Francis Nkrumah; I. Virginia Perkins; Robert J. Biggar; Paul 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 French ⚖ 366 KB

## Abstract Serial samples of sera from patients with African Burkitt's lymphoma were tested for antibody against Epstein‐Barr virus (EBV)‐specific membrane antigen (MA) by the antibody‐dependent cell‐mediated cytotoxicity assay (ADCC). Titers of patients in the long‐term survivor group were genera

Induction of cytotoxic T-cell response a
Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus
✍ O Bruña-Romero; J J Lasarte; G Wilkinson; K Grace; B Clarke; F Borrás-Cuesta; J 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 390 KB 👁 1 views

the development of new therapeutic methods are important A replication-defective recombinant adenovirus (RAd), goals for the future. RAdCMV-CE1, containing core and E1 genes of hepatitis Cytotoxic T lymphocytes (CTL) have been shown to play a C virus (HCV) was constructed. RAdCMV-CE1 was able major

Detection of neutralizing antibodies aga
Detection of neutralizing antibodies against human T-cell leukemia virus type 1 using a cell-free infection system and polymerase chain reaction
✍ Yuji Haraguchi; Da-Wei Yang; Atsushi Handa; Nobuaki Shimizu; Yuetsu Tanaka; Hiro 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 693 KB

We have developed a cell-free infection system to titrate neutralizing antibodies against human T-cell leukemia virus type I (HTLV-I) using the polymerase chain reaction (PCR). ## S+L-CCC (8C ) feline kidney or U-251 MG human glioma cells were infected with a cell-free culture supernatant derived

Vaccination against polyoma virus (PYV)
Vaccination against polyoma virus (PYV) tumors using vaccinia-PYV recombinants: A major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein
✍ M. P. Kieny; C. Gautier; C. Tomasetto; I. Kuhn; M. Hareuveni; P. Clertant; R. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 592 KB

## Abstract We previously reported that inoculation of rats with live vaccinia virus (VV) recombinants VVpyMT, VVpyLT expressing either the middle‐T (MT) or large‐T (LT) proteins of polyomavirus (PyV) can elicit immunity to challenge with syngeneic PyV‐tumor cells. We now report the results of cros